Clinical Trial Update: A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics [Phase 1]

View source ↗

Summary

Phase 1 study evaluating GSK256073, an HM74A receptor agonist, on glucose and NEFA levels in individuals with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GSK256073

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED